Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
IST:SELEC'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0.08 Med: 0.2 Max: 1.28
Current: 1.16
During the past 13 years, the highest Debt-to-EBITDA Ratio of Selcuk Ecza Deposu Ticaret venayi AS was 1.28. The lowest was 0.08. And the median was 0.20.
IST:SELEC's Debt-to-EBITDA is ranked better than 71.11% of 90
companies
in the Medical Distribution industry
Industry Median: 2.45
vs IST:SELEC: 1.16
Selcuk Ecza Deposu Ticaret venayi AS (IST:SELEC) Debt-to-EBITDA Explanation
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Selcuk Ecza Deposu Ticaret venayi AS Debt-to-EBITDA Related Terms
Selcuk Ecza Deposu Ticaret venayi AS Debt-to-EBITDA Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Selcuk Ecza Deposu Ticaret venayi AS Debt-to-EBITDA Chart
IST:SELEC vs MCK, CAH, COR: Debt-to-EBITDA Comparison
For the Medical Distribution subindustry, Selcuk Ecza Deposu Ticaret venayi AS's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Selcuk Ecza Deposu Ticaret venayi AS Debt-to-EBITDA vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Selcuk Ecza Deposu Ticaret venayi AS's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Selcuk Ecza Deposu Ticaret venayi AS's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Mar. 2026) EBITDA data.
Selcuk Ecza Deposu Ticaret venayi AS (IST:SELEC) has a Debt-to-EBITDA of 0.48 as of Mar. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Selcuk Ecza Deposu Ticaret venayi AS. This is 140% above median its historical median of 0.20. Over the past decade, Selcuk Ecza Deposu Ticaret venayi AS's Debt-to-EBITDA has ranged from 0.08 to 1.28. According to the industry distribution chart, Selcuk Ecza Deposu Ticaret venayi AS ranks #26 out of 90 companies in the Medical Distribution industry, placing it in the top 28.9%.
Is Selcuk Ecza Deposu Ticaret venayi AS's Debt-to-EBITDA too high?
Selcuk Ecza Deposu Ticaret venayi AS's current Debt-to-EBITDA of 0.48 is 140% above median its 10-year median of 0.20. Over the past 10 years, this metric has ranged from a low of 0.08 to a high of 1.28. The Medical Distribution industry median Debt-to-EBITDA is 2.45. Selcuk Ecza Deposu Ticaret venayi AS's value of 0.48 is 80.4% below this industry median. Based on the distribution chart, Selcuk Ecza Deposu Ticaret venayi AS ranks #26 out of 90 companies in the Medical Distribution industry, which is above the industry midpoint. Overall, Selcuk Ecza Deposu Ticaret venayi AS has a GF Score™ of 79/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Selcuk Ecza Deposu Ticaret venayi AS's Debt-to-EBITDA compare to MCK and CAH?
According to the Medical Distribution industry distribution chart, Selcuk Ecza Deposu Ticaret venayi AS ranks #26 out of 90 companies for Debt-to-EBITDA. This puts Selcuk Ecza Deposu Ticaret venayi AS in the upper half of its industry. The industry median Debt-to-EBITDA is 2.45. Selcuk Ecza Deposu Ticaret venayi AS's value of 0.48 is 80.4% below this benchmark. Historically, Selcuk Ecza Deposu Ticaret venayi AS's own Debt-to-EBITDA has ranged from 0.08 to 1.28 over the past decade. While the company's 10-year median is 0.20 vs. the industry median of 2.45, Selcuk Ecza Deposu Ticaret venayi AS has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Medical Distribution company?
The median Debt-to-EBITDA among Medical Distribution companies is 2.45, based on 90 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Selcuk Ecza Deposu Ticaret venayi AS's current Debt-to-EBITDA of 0.48 is 80.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Selcuk Ecza Deposu Ticaret venayi AS. For the Medical Distribution industry, the median Debt-to-EBITDA is 2.45 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Selcuk Ecza Deposu Ticaret venayi AS's current Debt-to-EBITDA is 0.48, which is 140% above median its own 10-year median of 0.20. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Selcuk Ecza Deposu Ticaret venayi AS stock overvalued right now?
Based on GuruFocus' analysis, Selcuk Ecza Deposu Ticaret venayi AS (IST:SELEC) is currently considered Significantly Overvalued. The stock's GF Value™ is ₺89.26, compared to a current price of ₺248.50 — trading 178.4% above its estimated fair value. The current Debt-to-EBITDA is 0.48, which is 140% above median its 10-year median of 0.20 and 80.4% below the Medical Distribution industry median of 2.45. Selcuk Ecza Deposu Ticaret venayi AS's overall GF Score™ is 79/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Selcuk Ecza Deposu Ticaret venayi AS (IST:SELEC), the current Debt-to-EBITDA is 0.48 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Selcuk Ecza Deposu Ticaret venayi AS (IST:SELEC) Overvalued in 2026?
Based on GuruFocus' analysis, Selcuk Ecza Deposu Ticaret venayi AS stock appears to be overvalued.
The current stock price of ₺248.50 is trading 178.4% above its estimated GF Value™ of ₺89.26.
GuruFocus considers Selcuk Ecza Deposu Ticaret venayi AS to be Significantly Overvalued.
Key valuation signals for IST:SELEC:
Debt-to-EBITDA: 0.48 (140% above median its 10-year median of 0.20)
GF Value™: ₺89.26 vs. price of ₺248.50 (178.4% above fair value)
Industry Position: 80.4% below the Medical Distribution median (#26 of 90)
No single metric tells the full story. See the IST:SELEC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Selcuk Ecza Deposu Ticaret venayi AS Business Description
Selcuk Ecza Deposu Ticaret ve Sanayi AS and its subsidiaries are in the business of export and import of drugs and patent medicines, medical supplies with pharmacy depot operations and also organize distribution channels between drug manufacturers, hospitals, and pharmacies. The company also distributes cosmetics, personal care, infant food, vitamins, medical and similar products.
79GF Score
Get the complete analysis for IST:SELEC
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
IST:SELEC has been successfully added to your 
